[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"effectiveness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:effectiveness":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,78,111,145,176,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100615924","a-study-on-the-efficacy-and-safety-of-telitacicept-in-the-treatment-of-children-ocular-myasthenia-gravis-100615924",false,"NCT07298928","A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis","The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health","Inclusion Criteria:\n\n1. The patient and their legal guardian voluntarily sign the informed consent form.\n2. Age \\\u003C 18 years, male or female.\n3. Diagnosis of OMG according to the Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis (2025 Edition).\n4. Stable administration of any one or combination of the following standard treatments prior to enrollment:\n\n   1. Cholinesterase inhibitors\n   2. Glucocorticoids\n\nExclusion Criteria:\n\n1. Active infection under treatment： Patients who are HBsAg positive must be excluded. Patients who are HBsAg negative but HBcAb positive must undergo quantitative HBV-DNA testing. Patients with a positive quantitative HBV-DNA result must be excluded; those with a negative result may be enrolled.\n2. Severe hepatic or renal insufficiency.\n3. Patients with malignant tumors other than thymoma.\n4. Patients within 3 months post-thymectomy.\n5. Hypogammaglobulinemia (IgG \\\u003C 400 mg\u002FdL) or IgA deficiency (IgA \\\u003C 10 mg\u002FdL).\n6. History of allergy to human-derived biological products.\n7. Participation in any other clinical trial within 28 days prior to enrollment or within 5 times the half-life of the investigational drug from the previous trial (whichever is longer).\n8. Patients deemed unsuitable for participation by the investigator (e.g., patients with severe psychiatric disorders).","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Under conventional treatment regimens, pediatric ocular myasthenia gravis (OMG) is prone to relapse and is associated with corticosteroid-related adverse effects, indicating an unmet clinical need. In May 2025, the targeted B-cell biologic agent Telitacicept was approved for use in adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (GMG) and subsequently initiated in national multicenter clinical trials for adult OMG. Our center published a retrospective study in the Chinese Journal of Evidence-Based Pediatrics in August 2025, which was the first report both domestically and internationally on the efficacy and safety of Telitacicept in four pediatric OMG patients. This study plans to conduct a prospective, multicenter, open-label, single-arm clinical trial aimed at evaluating the effectiveness and safety of Telitacicept in pediatric OMG.",[26],"Effectiveness",[28,29,30,31,32,33],"long-term follow-up","Ocular myasthenia gravis","Telitacicept","Children","Biological agent","Targeted treatment","NOT_YET_RECRUITING","2026-03-05",{"date":37,"type":38},"2026-03-06","ACTUAL",{"date":40,"type":20},"2026-03-10",{"date":42,"type":20},"2028-12",{"name":44,"class":45},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100614013","hospital-at-home-versus-inpatient-care-costs-and-effectiveness-100614013","NCT07274072","Hospital at Home Versus Inpatient Care: Costs and Effectiveness","Inclusion Criteria:\n\n* Inpatients in the hospital or patients in Hospital at Home care\n* Age ≥ 18 years\n* Admission due to a typical Hospital at Home diagnosis (mild to moderate inflammatory and infectious diseases of the lungs, urinary tract, gastrointestinal tract, heart, and skin; exacerbated chronic obstructive pulmonary disease; exacerbation of chronic heart failure; wounds; bleeding\u002Fanemia; dehydration; deterioration of general condition in multimorbid patients; infection-related complications in oncological patients; psychiatric problems including delirium; metabolic or autoimmune diseases; orthopedic patients; pain exacerbations of any cause; palliative patients up to and including terminal situations)\n* Patients without severe cognitive impairment or dysfunction who are capable of providing informed consent and\u002For completing the questionnaire\n* Patients with sufficient proficiency in written and spoken German and\u002For English\n\nExclusion Criteria:\n\n* Inpatient admission for other reasons\n* Refusal to provide informed consent",{"count":54,"type":20},200,"1 Day","OBSERVATIONAL","Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics. It bridges inpatient and outpatient care, working closely with hospitals, office-based physicians, home care services (Spitex), and therapy providers.\n\nThere are two main pathways:\n\nAdmission Avoidance: stable patients requiring hospitalization are admitted directly to HaH instead of an inpatient ward.\n\nEarly Supported Discharge: patients treated in hospital are discharged earlier than usual and transferred to HaH.\n\nEvidence International studies show HaH to be safe and effective. Reviews report comparable mortality and rehospitalization, shorter hospital stays, and cost advantages. Admission avoidance is linked to trends toward lower mortality and costs. Research showed similar mortality but fewer rehospitalizations, longer treatment duration, and reduced risks of institutionalization, depression, and anxiety. HaH patients were older, with reduced daily living activities, yet care costs were on average USD 5,054 lower than inpatient care.\n\nIn Switzerland, the mean hospital stay in 2019 was 8 days (acute somatic: 5.2; psychiatry: 33.5).\n\nStudy Hypotheses\n\nHaH can be delivered at equal or lower cost than regular hospitalization.\n\nHaH care is safe, with few complications, and yields high patient satisfaction.\n\nStudy Objective To demonstrate that hospital-equivalent home treatment of acutely ill patients is effective, appropriate, cost-efficient (according to Swiss WZW criteria), safe, and associated with high satisfaction and low complication rates compared with inpatient care.\n\nEndpoints\n\nPrimary: Costs - HaH vs. inpatient care at Hirslanden Clinic, using REKOLE® cost accounting.\n\nSecondary: Mortality, therapy type, monitoring, diagnostics, rehospitalization, complications, satisfaction, patient-reported outcomes, length of stay, referrals to nursing homes, follow-up after discharge, ED visits, rehabilitation referrals, and home care type.",[59,26,60],"Costs and Cost Analysis","Patient Satisfaction",[62,63,64,65],"hospital at home","costs","clinical outcome","patient satisfaction","RECRUITING","2025-12-09",{"date":69,"type":38},"2025-12-10",{"date":71,"type":38},"2025-09-01",{"date":73,"type":20},"2026-08-31",{"name":75,"class":76},"Hospital at Home AG","INDUSTRY",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":77},"100613273","evaluation-of-the-effectiveness-of-virtual-reality-headsets-with-hypnotic-scenarios-for-hygiene-care-in-patients-with-alzheimers-disease-or-related-disorders-with-behavioral-disturbances-100613273","NCT07264439","Evaluation of the Effectiveness of Virtual Reality Headsets With Hypnotic Scenarios for Hygiene Care in Patients With Alzheimer's Disease or Related Disorders With Behavioral Disturbances","Evaluation of the Effectiveness of Virtual Reality Headsets With Hypnotic Scenarios for Hygiene Care in Patients With Alzheimer's Disease or Related Disorders (ADRD) With Behavioral Disturbances","HYPNOGER 2","Inclusion Criteria:\n\n* Residents of the St-Victor center (CHU Amiens-Picardie), including nursing home units, reinforced care units, and long-term care units;\n* Patients diagnosed with ADRD presenting opposition or agitation during hygiene and toileting care;\n* Affiliation to a social security scheme,\n* Informed consent signed by the patient or legal representative.\n\nExclusion Criteria:\n\n* Residents in terminal palliative care.",{"count":87,"type":20},24,[23],"A device combining a virtual reality (VR) headset with hypnotic scenarios may represent an effective tool to reduce anxiety and opposition during hygiene care in patients with neurocognitive disorders presenting with behavioral and psychological symptoms.\n\nThe primary objective of this project is to assess the feasibility and effectiveness of VR headsets with hypnotic scenarios compared with standard care in patients with ADRD presenting behavioral disturbances during hygiene care.",[26,91,92,93,94,95],"Virtual Reality","Hypnotic Scenarios","Hygiene Care","Alzheimer's Disease and Related Disorders (ADRD)","Behavioral Disturbances",[26,97,98,99,100,101],"virtual reality","hypnotic scenarios","hygiene care","Alzheimer's disease and related disorders (ADRD)","behavioral disturbances","2025-12-02",{"date":104,"type":38},"2025-12-04",{"date":106,"type":38},"2025-09-03",{"date":108,"type":20},"2027-05",{"name":110,"class":45},"Centre Hospitalier Universitaire, Amiens",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100587526","pharmacogenomics-supported-psychotropic-prescribing-trial-100587526","NCT06929533","Pharmacogenomics-Supported Psychotropic Prescribing Trial","Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba","PGx-SUPPORT","Inclusion Criteria:\n\n* Aged 18 years or older\n* The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated\n* The treating clinician thinks PGx testing can benefit and refers the patient to the study\n\nExclusion Criteria:\n\n* Unwillingness to donate saliva samples for genetic analysis\n* History of liver or bone marrow (hematopoietic cell) transplantation\n* PGx testing results are already available\n* No personal health identification number (PHIN) is available",{"count":54,"type":20},[23],"Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.",[123,124,125,26],"Mental Disorder","Pharmacogenetics","Adverse Drug Reaction (ADR)",[127,128,129,124,130,131,132,133,134,135],"Adult","Mental Health","Psychiatry","Depression","Anxiety","OCD","Psychosis","Bipolar Disorder","mental illness",{"date":137,"type":38},"2025-09-08",{"date":139,"type":38},"2025-07-01",{"date":141,"type":20},"2030-12-31",{"name":143,"class":45},"University of Manitoba",2,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":77},"100592388","effectiveness-and-acceptability-of-remote-fine-tuning-of-hearing-aids-in-danish-adults-100592388","NCT06992778","Effectiveness and Acceptability of Remote Fine-Tuning of Hearing Aids in Danish Adults","Exploring the Effectiveness and Acceptability of Remote Fine-Tuning of Hearing Aids in Danish Adults: A Non-blinded, Non-inferiority Randomized Controlled Trial With an Embedded Qualitative Study","EARFit","Inclusion Criteria:\n\n* Adult patients with hearing loss who desire HA treatment (+18 of age).\n* Danish language skills both written and oral.\n* Acquisition of digital proficiency in terms of being familiar with operating a smartphone, including navigating menus, opening and closing apps, and interacting with the touchscreen with capabilities for audio and video calls.\n* Access to a smartphone that are compatible with manufacturers' system requirements.\n* Access to a stable network connection on the mobile device, with either Wi-Fi or mobile data.\n\nExclusion Criteria:\n\n* Patients with tinnitus requiring treatment or scoring more than 58 in the 'Tinnitus Handicap Inventory' (THI) grading system.\n* Patients with Ménière disease, due to its complications and symptoms as dizziness, balance problems and fluctuating hearing loss, that can affect the HA treatment.\n* Patients who will receive in-the-ear (ITE) hearing aids, due to potential limitations in connectivity for remote fine-tuning.\n* Patients which are recommended\u002Foffered unilateral HA treatment.",{"count":154,"type":20},120,[23],"The aim of this clinical trial is to evaluate the effectiveness and user satisfaction of remote fine-tuning of hearing aids compared to traditional face-to-face adjustments. The main questions aims to answer:\n\n\\- Are hearing aid outcomes (self-reported and objective) similar when using remote fine-tuning compared to face-to-face adjustments?\n\nResearchers will compare remote fine-tuning (using a smartphone app) to traditional face-to-face fine-tuning sessions in a clinical setting.\n\nParticipants will:\n\n* Be randomized to either the remote fine-tuning group (intervention group) or the face-to-face adjustment group (control group).\n* Attend five scheduled consultations over a 3-month period, including baseline measurements, hearing aid fittings, and follow-up visits.\n\nParticipants in the remote fine-tuning group will:\n\n\\- Set up and use a hearing aid manufacturer's smartphone app to complete fine-tuning sessions from home.\n\nParticipants in the face-to-face group will:\n\n\\- Visit the clinic for in-person fine-tuning appointments.\n\nData will be collected through questionnaires (e.g., SSQ-12, IOI-HA, and COSI) and objective measures such as the Speech Intelligibility Index (SII) and speech comprehension in noise (DS-FF). Additional qualitative data will be gathered from interviews with participants in the remote fine-tuning group.",[158,159,160,26],"Hearing Aid","Telehealth","Hearing Aid Fitting",[162,163,164,165,166],"Remote fine-tuning","Teleaudiology","Randomized controlled trial (RCT)","Hearing aids","Denmark","2025-08-13",{"date":169,"type":38},"2025-08-14",{"date":171,"type":38},"2025-05-27",{"date":173,"type":20},"2026-03-30",{"name":175,"class":45},"Zealand University Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":183,"sex":16,"minAge":17,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":189,"conditions":190,"keywords":195,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":77},"100587883","phase-2-cultural-adaptation-of-a-web-based-app-myplan-thailand-to-empower-and-support-friends-and-family-of-intimate-partner-violence-survivors-100587883","NCT06934174","Cultural Adaptation of a Web-Based App (myPlan Thailand) to Empower and Support Friends and Family of Intimate Partner Violence Survivors","IPV","Inclusion Criteria:\n\n* being female or males who have a female friend currently (past 6 months) experiencing IPV\n* Thai speaking\u002Freading\n* At least 18 years old\n* Have access to a safe smart-phone or computer with internet\n* Have safe email address\n* Living in Thailand\n\nExclusion Criteria:\n\n* Cannot speak\u002Freading Thai\n* Less than age 18 years old\n* Cannot access to a safe smartphone or computer with internet\n* Not living in Thailand",true,"60 Years",{"count":186,"type":20},100,[188],"PHASE2","This research will support and empower friends\u002Ffamily (F\u002FF) of intimate partner violence (IPV) survivors in Thailand, where IPV is critical and common, and survivors first and foremost seek help for abuse from their F\u002FF. myPlan app (www.myPlanapp.org) is a free mobile evidence-based intervention app to prevent IPV. The app was first developed in the United States (US) and has been disseminated to high-income countries (e.g., New Zealand, Canada, Australia) and lowincome (Kenya). One new hope for improving survivors' psychological and well-being is adapting and introducing the myPlan app for the concerned friends\u002Ffamily who support survivors in Thailand.\n\nTherefore, the propose of this longitudinal research study, Cultural Adaptation of a Web-Based App (myPlan Thailand) to Empower and Support Friends\u002FFamily of Intimate Partner Violence Survivors in Thailand, will have two consecutive phases with three aims: 1) To tailor the myPlan app content for concerned F\u002FF members of Thai IPV survivors, 2) To integrate the adapted myPlan app content for concerned F\u002FF members of Thai IPV survivors, 3) To test the feasibility and acceptability of the adapted myPlan app with concerned F\u002FF members of Thai IPV survivors. Phase 1 (Year 1-2) will achieve aim 1-2 to tailor the myPlan app with Thai survivors and friends\u002Ffamily. The investigators will review current content and conduct in-depth interviews with survivors and concerned F\u002FF members on social norms associated with IPV, informal support systems and the role\u002Fresponsibility in helping survivors, safety strategies used by concerned F\u002FF members and negative consequences for both survivor and F\u002FF member providing support. Moreover, in phase 1, the adapted content will be pilot tested with concerned F\u002FF members of survivors by using cognitive techniques and theater-testing methodology.\n\nPhase 2 (Year 3-4) will achieve aim 3 to test the feasibility and acceptability of the adapted myPlan app with F\u002FF. The investigators will conduct a two-group RCT design with concerned F\u002FF member randomized to receive a) the myPlan app for F\u002FF member, or b) standard usual-care safety planning information. Primary outcomes for F\u002FF members include change in knowledge and attitudes towards IPV and F\u002FF empowerment to plan and take safety support survivor. Secondary outcomes will examine change in F\u002FF' distress, frustration and consequences for supporting the survivor. This phase will also collect feasibility and acceptability data to informed a planned R01 submission in Year 3 of the study. The K43 application outlines a four-year plan to support a candidate who is a nursing instructor with 15 years of work in diverse projects, settings, and disciplines; which positions her for a successful career as an independent researcher in research field of intimate partner violence. The career development plan provides a sequence of carefully selected training and mentoring experiences, including coursework to increase research capacity, leadership skills, mentored research leading to a R01 proposal, peer reviewed publications, and professional networking, that will catapult this research to the next level of research achievement. The team will be a collaboration between the Boromarajonani College of Nursing Khon Kaen (BCNKK), Khon Kaen One Stop Crisis Center (OSCC), Johns Hopkins University (JHU), Notre Dame of Maryland University (NDM), and Auckland University of Technology (AUT), New Zealand.",[191,192,193,194,26],"Intimate Partner Violence (IPV)","Social Support","Empowerment","mHealth",[196,197,198,199,200,201],"Intimate partner violence","Friends\u002FFamily memeber","Safety","Social support","mHealth intervention","Thailand","2025-05-08",{"date":204,"type":38},"2025-05-13",{"date":206,"type":38},"2025-04-17",{"date":208,"type":20},"2026-06",{"name":210,"class":45},"Boromarajonani College of Nursing, Khon Kaen",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":77},"100486729","phase-2-lenvatinib-for-advanced-bone-and-soft-tissue-sarcoma-100486729","NCT05617859","Lenvatinib for Advanced Bone and Soft Tissue Sarcoma","A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure","Inclusion Criteria:\n\n1. Ages 10-70, both male and female.\n2. The Eastern Collaborative Oncology Group (ECOG) physical status score was 0-1. Subjects with amputation can be relaxed up to 2 points.\n3. The expected survival time was ≥3 months.\n4. Subjects with bone and soft tissue sarcomas with distant metastases or locally advanced disease who were not considered suitable for surgical treatment by the investigator.\n5. Patients who had been treated with apatinib or anlotinib in the past, and the efficacy was evaluated as CR\\\\PR\\\\SD\\\\PD, and had no response to other systemic therapy after drug resistance, or had reprogression after more than 3 months.\n6. There were measurable lesions that met RECIST1.1 criteria.\n7. All acute toxicities from previous antitumor therapy or surgery resolved to grade 0-1 (according to NCI-CTCAE, version 4.03) or to enrollment\u002Fexclusion criteria by day 1 of the first cycle (C1D1), except for toxicities such as hair loss that the investigator considered to pose no safety risk to the subject.\n8. Adequate organ and bone marrow function is defined as follows:\n\n   Blood routine (no blood transfusion, no G-CSF, no medication correction within 14 days before screening) :\n\n   Neutrophil count (ANC)≥1,500\u002Fmm3(1.5×109\u002FL); Platelet count (PLT)≥100,000\u002Fmm3(100×109\u002FL); Hemoglobin (Hb)≥9g\u002FdL(90g\u002FL);\n\n   Blood biochemical:\n\n   Serum creatinine (Cr)≤1.5× upper limit of normal (ULN) or creatinine clearance (Cockroft-Gault formula)≥60ml\u002Fmin; Total bilirubin (TBIL)≤1.5×ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≤2.5×ULN, and subjects with liver metastases should ≤5×ULN;\n\n   Blood coagulation function:\n\n   International normalized ratio (INR)≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN;\n9. Urine routine: urinary protein \\\u003C2+; If urine protein ≥2+, 24-hour urine protein quantification must show protein ≤1g;\n10. Thyroid function: Thyroid stimulating hormone (TSH)≤ULN; FT3(T3) and FT4(T4) levels should be examined if they are abnormal, and normal FT3(T3) and FT4(T4) levels can be selected.\n11. Female subjects of reproductive age must have a negative serum pregnancy test within 7 days prior to medication and be willing to use a medically approved highly effective contraceptive (e.g., intrauterine device, birth control pill, or condom) during the study period and within 3 months after the last administration of the study drug; Male subjects with a female partner of reproductive age were required to undergo surgical sterilization or consent to use an effective method of contraception during the study period and for 3 months after the last study dose.\n12. I have AGREED and signed the informed CONSENT, and I am willing AND ABLE TO comply with the planned visit, study treatment, laboratory tests and other trial procedures.\n\nExclusion Criteria:\n\n1. C1D1 received the following treatments in the previous 4 weeks:\n\n   Radiotherapy, surgery, chemotherapy, immunotherapy for tumors. Other investigational drugs. Get live attenuated vaccine.\n2. Surgery and\u002For radiation therapy for bone and soft tissue sarcomas were planned during the study.\n3. Previous use of immunosuppressive drugs within 14 days prior to C1D1, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (i.e., no more than 10mg\u002F day of prednisolone or an equivalent physiological dose of another corticosteroid).\n4. Severe infection (such as the need for intravenous antibiotic, antifungal, or antiviral medication) within 4 weeks prior to C1D1, or unexplained fever \\>38.5°C during the screening period\u002Fbefore the first dose.\n5. Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90mmHg).\n6. Significant bleeding symptoms or clear bleeding tendency occurred within 3 months before C1D1, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, vasculitis, etc. Or arteriovenous thrombotic events occurring within 6 months before C1D1, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin or long-term antiplatelet therapy (aspirin ≥300mg\u002F day or clopidogrel ≥75mg\u002F day) may be required.\n7. Active heart disease in the 6 months prior to C1D1, including myocardial infarction and severe\u002Funstable angina pectoris. Left ventricular ejection fraction \\\u003C50% on echocardiography, poorly controlled arrhythmias (including QTcF interval \\>450ms in men and \\>470ms in women).\n8. C1D1 had been diagnosed with any other malignancy within 3 years prior to C1D1, except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix.\n9. Known allergy to the study drug or any of its excipients.\n10. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B surface antigen positive and HBVDNA≥500IU\u002Fml), and hepatitis C (hepatitis C antibody positive and HCV-RNA above the detection limit of the assay).\n11. Concomitant diseases (e.g., poorly controlled hypertension, severe diabetes,neurological or mental disorders, etc.) or any other conditions that, in the judgment of the investigator, seriously endanger the safety of the subjects, may confounding the results of the study, or interfere with the completion of the study.","10 Years","70 Years",{"count":221,"type":20},60,[188],"A total of 60 patients with metastatic\u002Fsurgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.",[26,225],"Sexuality","2023-08-17",{"date":228,"type":38},"2023-08-21",{"date":230,"type":38},"2023-04-30",{"date":232,"type":20},"2026-12-31",{"name":234,"class":235},"Henan Cancer Hospital","OTHER_GOV"]